Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Today, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock received an upgrade by Bank of America from Underperform to Neutral.
There are 0 sell ratings, 4 hold ratings, 5 buy ratings, 0 strong buy ratings on the stock.
The current consensus rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Buy with a consensus target price of $8.8333 per share, a potential 40.66% upside.
Some recent analyst ratings include
- 7/17/2018-Bank of America Upgrade from a “Underperform ” rating to a ” Neutral” rating.
- 6/28/2018-Seaport Global Securities Reiterated Rating of Neutral.
- 1/23/2018-HC Wainwright Reiterated Rating of Buy.
- 1/2/2018-Royal Bank of Canada Upgrade from a “Sector Perform ” rating to a ” Outperform” rating.
- 12/20/2017-Barclays initiated coverage with a Equal Weight rating.
- 9/6/2017-Jefferies Financial Group Upgrade from a “Hold ” rating to a ” Buy” rating.
Recent Insider Trading Activity For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has insider ownership of 5.21% and institutional ownership of 89.91%.
- On 6/1/2018 William P Sheridan, CMO, sold 42,112 with an average share price of $6.30 per share and the total transaction amounting to $265,305.60.
- On 11/13/2017 William P Sheridan, CMO, sold 64,310 with an average share price of $4.72 per share and the total transaction amounting to $303,543.20.
- On 9/18/2017 Fred E Cohen, Director, sold 54,250 with an average share price of $5.42 per share and the total transaction amounting to $294,035.00.
- On 3/20/2017 Thomas R Staab II, CFO, sold 3,250 with an average share price of $9.20 per share and the total transaction amounting to $29,900.00.
- On 3/10/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $9.06 per share and the total transaction amounting to $29,445.00.
- On 3/8/2017 Thomas R Staab II, Insider, sold 6,500 with an average share price of $8.43 per share and the total transaction amounting to $54,795.00.
- On 3/6/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $7.90 per share and the total transaction amounting to $25,675.00.
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Recent Trading Activity for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Shares of BioCryst Pharmaceuticals, Inc. closed the previous trading session at 6.28 up +0.080 1.29% with 6.46 shares trading hands.